Complizen Learn

International medical device manufacturers often run into the same avoidable U.S. market-entry mistakes: assuming CE-mark experience will translate cleanly to FDA, choosing the wrong predicate strategy, trying to reuse EU clinical data without reframing it for substantial equivalence, misunderstanding when a U.S. Agent is needed, missing U.S.-specific testing expectations, underestimating the burden of Additional Information requests, overlooking remaining QMSR gaps after ISO

Tariffs are usually discussed in terms of trade policy, manufacturing costs, and geopolitics. But in the global medical device industry, they may be doing something else entirely. They are quietly creating the next wave of companies entering the U.S. healthcare market. Across Southeast Asia and other emerging manufacturing hubs, medical device manufacturers that historically focused on contract production are beginning to ask a different question: What if we sold directly int

When Kintsugi shut down, a lot of people filed it under “clinical AI is hard.” That’s true, but incomplete. Kintsugi is a clean case study in something more important, the regulatory path can be scientifically valid and still economically fatal. You can build a real product, run serious pilots, pursue FDA the right way, and still lose because your runway is measured in months while regulatory certainty is measured in years. If you build in medtech, this is not a rare edge cas

AI can speed up 510(k) predicate research by 70-80%, find relevant FDA guidance in minutes instead of hours, and organize evidence trails automatically. But AI cannot make regulatory strategy decisions, replace required testing, or take accountability for submission content. Best results: Use AI for research-heavy tasks (finding predicates, FDA guidance, standards), pair with regulatory consultant for strategy and review. Cost comparison: AI tools $200-$2K/month vs. consultan

For many international medical device manufacturers, entering the US market carries a particular kind of weight. The FDA is seen as conservative. Documentation is assumed to be heavier. Reviews are thought to be unpredictable. So the US often feels like a fundamentally harder market. In practice, most of the difficulty teams encounter does not come from stricter rules or higher scientific standards. It comes from confusion about where to start, what applies, and how to transl

Most people assume regulatory work is slow because the rules are hard. The requirements are strict, the stakes are high, and mistakes are costly. Long timelines feel unavoidable. In practice, that’s not what actually slows teams down. Regulatory work isn’t slow because it’s complex. It’s slow because of how information is handled. Key takeaways Regulatory teams lose time searching instead of making decisions Scattered information makes work harder to defend and repeat Small g

CMS New Technology Add-on Payment (NTAP) is the fastest path to Medicare reimbursement for by providing additional Medicare payments...

The EU AI Act is a risk-based regulation requiring AI medical devices to undergo dual compliance, single integrated CE: NB assesses AIA +...

EU AI Act requires separate AI system certification alongside medical device approval, with 36-month implementation timeline. FDA's PCCP...

IMDRF is the global forum harmonizing medical device regulations across major markets (FDA, MHRA, Health Canada, EU). On Jan, 2025, IMDRF...

Medical device companies expanding globally face a critical strategic decision: which regulatory pathway offers the fastest, most...

Medical device startups have 8 primary funding sources: government grants ($305K-$3M, non-dilutive), angel investors ($50K-$2M, 10-25% equity), venture capital ($1M-$100M+, 15-30% equity per round), crowdfunding ($50K-$1M, variable terms), accelerators ($25K-$250K + mentorship), corporate partnerships, revenue-based financing, and bootstrapping. The smart play is sequencing: validate with grants, bridge with angels, then scale with venture—layering in partnerships or revenue-

Medical device development costs vary by classification: Class I ($200K-$2M), Class II ($2M-$30M), and Class III ($5M-$119M+). Major expenses include clinical trials (40-60% of budget), regulatory activities (10-15%), manufacturing setup (15-25%), and commercialization (10-20%). Timeline spans 1-7 years depending on complexity and pathway. The #1 question every medtech entrepreneur asks: "How much funding do I actually need?" The answer depends on your device classification,

FDA is replacing 21 CFR 820 (Quality System Regulation) with the Quality Management System Regulation (QMSR) on February 2, 2026,...

An FDA Warning Letter  is a public advisory  notice that cites significant violations  and requests a written response—typically within...

Most SaMD 510(k)s  hit a first-cycle Additional Information (AI) letter , not a final rejection. The recurring issues: missing...

Sam Altman’s June 10, 2025 essay, “ The Gentle Singularity ,”  sketches a near-term AI timeline—2025 agents doing real cognitive work,...

In 2025, FDA reviews a risk-based  software evidence package per the Device Software Functions (DSF)  guidance: choose Basic  or Enhanced...

FDA’s Jan 7, 2025 draft  for AI-enabled device software functions  recommends including: model description, dataset lineage/partitions...

Starting October 1, 2025 , all De Novo requests for SaMD  must be submitted using the FDA’s eSTAR template . This shift brings new module...